Helicobacter pylori infection and gastroesophageal cancer: Unveiling a Hamletic dilemma

Annals of Gastroenterology

Volumn 27, Issue 4, 2014, Pages 291-293

  Zullo, Angelo ^a   Hassan, Cesare ^a   De Francesco, Vincenzo ^b   Manta, Raffaele ^c   Romiti, Adriana ^d   Gatta, Luigi ^e  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b Riuniti Hospital   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e Versilia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ATROPHIC GASTRITIS; BARRETT ESOPHAGUS; DISEASE ASSOCIATION; DYSPEPSIA; EDITORIAL; ERADICATION THERAPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROESOPHAGEAL CANCER; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER PRESSURE; NON EROSIVE REFLUX DISEASE; OBESITY; PEPTIC ULCER; REFLUX ESOPHAGITIS; STOMACH CANCER;

EID: 84920371314     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Editorial

References (28)

1. Keighley MR. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther 2003;18(Suppl 3):7-30.
2. Abrams JA, Gonsalves L, Neugut AI. Diverging trends in the incidence of reflux-related and Helicobacter pylori-related gastric cardia cancer. J Clin Gastroenterol 2013;47:322-327.
3. Schistosomes, liver flukes and Helicobacter pylori. IARC Working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
4. Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett’s esophagus. Am J Gastroenterol 2000;95:2206-2211.
5. Corley DA, Kubo A, Levin TR, et al. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut 2008;57:727-733.
6. Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010;139:73-83.
7. Xia HH, Talley NJ. Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: an unexplored triangle. Am J Gastroenterol 1998;93:394-400.
8. Graham DY, Opekun AR, Osato MS, et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004;53:1235-1243.
9. Matos JI, de Sousa HA, Marcos-Pinto R, et al. Helicobacter pylori CagA and VacA genotypes and gastric phenotype: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:1431-1441.
10. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 03/07/2014.
11. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
12. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174.
13. Blaser MJ. Helicobacter pylori and esophageal disease: wake-up call? Gastroenterology 2010;139:1819-1822.
14. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-664.
15. Rubenstein JH, Inadomi JM, Scheiman J, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2014;12:239-245.
16. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012;47:129-135.
17. Moschos JM, Kouklakis G, Vradelis S, et al. Patients wiThestablished gastroesophageal reflux disease might benefit from Helicobacter pylori eradication. Ann Gastroenterol 2014;27:352-356.
18. Zullo A, Hassan C, Repici A, Bruzzese V. Helicobacter pylori eradication and reflux disease onset: did gastric acid get "crazy"? World J Gastroenterol 2013;19:786-789.
19. Lagergren JE, Bergström E, Lindergren A, Nuren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
20. Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. Pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci 2010;55:3124-3131.
21. Morini S, Zullo A, Hassan C, Lorenzetti R, Stella F, Martini MT. Gastric cardia inflammation: role of Helicobacter pylori infection and symptoms of gastroesophageal reflux disease. Am J Gastroenterol 2001;96:2337-2340.
22. Yang L, Chaudhary N, Baghdadi J, Pei Z. Microbiome in reflux disorders and esophageal adenocarcinoma. Cancer J 2014;20:207-210.
23. Pate RR, O’Neill JR, Liese AD, et al. Factors associated with development of excessive fatness in children and adolescents: a review of prospective studies. Obes Rev 2013;14:645-658.
24. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013;310:627-636.
25. Carabotti M, D’Ercole C, Iossa A, Corazziari E, Silecchia G, Severi C. Helicobacter pylori infection in obesity and its clinical outcome after bariatric surgery. World J Gastroenterol 2014;20:647-653.
26. Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 2014;27:27-33.
27. Alakkari A, Zullo A, O’Connor HJ. Helicobacter pylori and nonmalignant diseases. Helicobacter 2011;16(Suppl 1):33-37.
28. Caselli MI, Zullo A, Maconi G, et al. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007;39:782-789.